Successful testing in complementary animal models (e.g. human ACE2-transgenic hamsters)59 will warrant further development of YF-S0* as a second-generation COVID-19 vaccine candidate with broader coverage of relevant virus strains. Here, ACE2 is linked to COVID-19.